Allogeneic hematopoietic stem cell transplantation - Yesterday, today, and tomorrow
Allogeneic hematopoietic stem cell transplantation - Yesterday, today, and tomorrow
复制标题
DOI：
10.1016/s0301-472x(02)01020-2
复制
发表时间：
2003-01-01
影响因子：
2.6
通讯作者：
Storb, R
中科院分区：
文献类型：
--
作者：
Storb, R
在过去的50年中，对造血干细胞移植（HSCT）用于治疗癌症和非恶性血液病的深入研究已经将这种治疗方式从被认为是由难以克服的并发症困扰的治疗方式改变为现在是某些疾病的标准治疗方式。最近的研究已经开辟了一条道路，包括老年患者与各种血液恶性疾病。全世界移植团队的持续研究可能会使开发新的和改进的治疗方式以及多能造血干细胞在人类疾病治疗中的更广泛应用取得持续进展。(C)2003年国际实验血液学学会。出版社：Elsevier Science Inc.
During the past 50 years, intensive studies into the use of hematopoietic stem cell transplantation (HSCT) for therapy of cancer and nonmalignant hematologic diseases have changed this treatment modality from one that was thought to be plagued by insurmountable complications to one that is now standard therapy for some diseases. More-recent research has opened up the way to include elderly patients with a wide variety of hematologic malignant diseases. Continued research by transplant teams worldwide is likely to allow continued progress toward developing novel and improved treatment modalities and even wider application of the use of pluripotent hematopoietic stem cells in the treatment of human diseases. (C) 2003 International Society for Experimental Hematology. Published by Elsevier Science Inc.